• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Asia

BioWorld Asia

Oct. 3, 2018

View Archived Issues

Verastem taps CSPC as China partner for cancer drug Copiktra

HONG KONG – With the U.S. approval under its belt, Verastem Inc. is looking at China as the next big market for Copiktra (duvelisib), inking an exclusive licensing deal with CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, in exchange for $15 million up front in deal for rights to develop and commercialize Copiktra for all oncology indications in China. Read More

Checkpoint inhibition work earns Nobel for Kyoto's Honjo, MD Anderson's Allison

LONDON – Braced for canceled classes after Typhoon Trami crossed west Japan overnight on Sunday, Kyoto University instead found itself swept up in a far more genial atmosphere, as news broke Monday that Tasuku Honjo, staff member since 1984, had won the 2018 Nobel prize in physiology or medicine. Read More

Iceland's Alvotech partners with China's Changchun to develop biosimilars

Alvotech ehf., of Iceland, and an independent sister company of U.S. pharmaceutical firm Alvogen Group Inc., recently joined hands with China's Changchun High & New Technology Industries Group Inc. to develop, manufacture and commercialize Alvotech's biosimilars in the Asian country. The collaboration will see a new joint venture with manufacturing capabilities in China's Jilin province, which will be equally funded by both companies. Read More

Amgen's Blincyto enters Asia market via approval for ALL patients in Japan

HONG KONG – Japan's Ministry of Health, Labour and Welfare gave the nod to Blincyto (blinatumomab) for use in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), marking the bispecific T-cell engager's entry into the Asian market, following approvals in the U.S., all members of the EU and European Economic Area, Canada and Australia. Read More

Increasing globalization in biopharma highlights differing management styles, cultures

HONG KONG – The recent M&A deal between Japan's 237-year-old Takeda Pharmaceutical Co. Ltd. and Irish firm Shire plc has attracted massive attention, not just because of the mammoth size of the deal but also the tug of war among the Japanese company's shareholders, a group of which made a failed attempt to block the deal during Takeda's general meeting earlier this year. Read More

Vaccination largely prevented Chinese H7N9 avian flu infection

The highly pathogenic H7N9 avian influenza viruses that emerged in China in 2017 evolved rapidly into different viral subtypes and genotypes, which were largely controlled by mass vaccination of chickens, a Chinese Academy of Agricultural Sciences (CAAS) study has established. Read More

Other news to note

Chugai Pharmaceutical Co. Ltd., of Tokyo, and Eli Lilly and Co., of Indianapolis, said they entered a license agreement for OWL-833, Chugai's oral non-peptidic GLP-1 receptor agonist, which is a phase I-ready asset that is being studied for the treatment of type 2 diabetes.  Read More

Astrazeneca celebrates 70 years in Taiwan with $32.5M R&D investment

TAIPEI, Taiwan – Astrazeneca plc said recently it would make a TWD1 billion (US$32.5 million) R&D investment in Taiwan over the coming three years, nearly tripling its clinical R&D spending. The company said that investment will drive the roll-out of 10 new medicines by 2021, which will target ovarian cancer, lung cancer, severe asthma and diabetes. Read More

Regulatory actions for Sept. 25 – Oct. 1, 2018

Read More

Clinical data for Sept. 25 – Oct. 1, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe